Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026837 (
muscle rigidity
)
1,077
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of the present study was to find out whether the classic neuroleptic fluphenazine is a good model compound for inducing parkinsonian-like
muscle rigidity
in rats. The muscle tone was measured as resistance developed by the rat's hind foot to passive flexion and extension.
Fluphenazine
in doses of 0.4-3.0 mg/kg i.p. induced a dose-dependent increase in the hind foot resistance to passive movements. The
muscle rigidity
induced by fluphenazine 1.5 mg/kg i.p.) was counteracted in a dose-dependent manner by the main antiparkinsonian drug L-DOPA (25-75 mg/kg i.p.). The present results suggest that the fluphenazine-induced
muscle rigidity
may be a useful model of parkinsonian rigidity.
...
PMID:Muscle rigidity induced by fluphenazine in rats is antagonized by L-DOPA, an antiparkinsonian drug. 967 Jan 14